Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Atreca, Inc. - Class A Common Stock (NQ: BCEL )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Mar 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Atreca, Inc. - Class A Common Stock

BCEL Stock Alert: Halper Sadeh LLC Is Investigating Atreca, Inc.
From Halper Sadeh LLC
Via Business Wire
Atreca Announces Asset Purchase Agreement for Sale of Antibody-Related Assets and Materials to Immunome
From Atreca, Inc.
Via GlobeNewswire
Atreca Reports Third Quarter 2023 Financial Results and Announces Further Reorganization to Support Exploration of Strategic Alternatives
From Atreca, Inc.
Via GlobeNewswire
Atreca Announces Agreement to Terminate Lease and Departure of Chief Financial Officer Herb Cross
From Atreca, Inc.
Via GlobeNewswire
Atreca Reports Second Quarter 2023 Financial Results and Announces Corporate Restructuring
From Atreca, Inc.
Via GlobeNewswire
Atreca Presents Data from Ongoing Phase 1b Study of ATRC-101 in Patients with Select Advanced Solid Tumors during Oral Abstract Session at the ASCO 2023 Annual Meeting
From Atreca, Inc.
Via GlobeNewswire
Atreca Reports First Quarter 2023 Financial Results and Recent Corporate Developments
From Atreca, Inc.
Via GlobeNewswire
Atreca Announces Oral Presentation of ATRC-101 Phase 1b Study Data at ASCO 2023 Annual Meeting
From Atreca, Inc.
Via GlobeNewswire
Atreca to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference
From Atreca, Inc.
Via GlobeNewswire
Atreca Reports Fourth Quarter and Full-Year 2022 Financial Results and ATRC-101 Data Update
From Atreca, Inc.
Via GlobeNewswire
Atreca to Host Fourth Quarter and Year End 2022 Conference Call and Webcast on March 29, 2023
Call/webcast to feature updates on the discovery platform and pipeline, including updated data from the ongoing Phase 1b trial of ATRC-101 
From Atreca, Inc.
Via GlobeNewswire
Atreca to Participate at Cowen’s 43rd Annual Health Care Conference
From Atreca, Inc.
Via GlobeNewswire
Atreca and Xencor to Develop T Cell Engaging Bispecific Antibody Directed Against Novel Solid Tumor Target
From Atreca, Inc.
Via GlobeNewswire
Atreca Appoints Philippe Bishop, MD as Chief Medical Officer
From Atreca, Inc.
Via GlobeNewswire
Atreca Reports Third Quarter 2022 Financial Results and Provides Pipeline Update
From Atreca, Inc.
Via GlobeNewswire
Atreca to Present at Upcoming Investor Conferences
From Atreca, Inc.
Via GlobeNewswire
Atreca Announces Poster Presentations at Society for Immunotherapy of Cancer (SITC) Annual Meeting
From Atreca, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.